The European Congress on Obesity starts on 12 May 2026, and this year’s programme is especially relevant for anyone tracking GLP-1 tablets, oral semaglutide, CagriSema and the next wave of obesity medicines. The useful UK angle is not that a conference creates access. It is that new data can quickly change how readers understand the pipeline, the oral-vs-injection debate and the difference between a trial signal and a treatment route.
Key facts at a glance
12-15 May 2026, Istanbul
Oral semaglutide, higher-dose semaglutide, CagriSema and amylin-based therapies
Evidence watch, not instant UK availability
What is happening this week
ECO 2026 runs from 12 to 15 May 2026. The official programme confirms a major obesity-medicine agenda, and Novo Nordisk’s congress hub lists sessions covering semaglutide in clinical practice, oral and injectable pathways, and amylin-based therapies including CagriSema and zenagamtide. The company has also signalled a large data presence at the meeting, including work around Wegovy, higher-dose semaglutide, oral semaglutide and CagriSema.
That matters because the GLP-1 story is no longer just “which weekly injection loses most weight”. The market is moving into route, convenience, adherence, cardiovascular risk, body-composition questions, real-world engagement and combination medicines. Those are exactly the details that can separate a useful update from a thin headline.
Why this matters for GLP-1 tablet readers
Tablet readers are often trying to answer a practical question: is there a pill version, and is it available in the UK? Conference data does not answer that by itself. But it can change the background evidence picture. If oral semaglutide results, oral pathway data or combination-therapy findings become stronger, the “tablet future” feels less theoretical. If tolerability, dosing or adherence questions look difficult, the article should say that too.
The editorial job is to keep those layers separate. Evidence can become stronger before access changes. A company can present promising data before regulators decide anything. A U.S. or European development can be relevant without being a British prescribing route. That separation is what keeps the news useful rather than breathless.
ECO 2026 is a good week to publish GLP-1 pipeline coverage, but every story should label whether it is trial evidence, regulatory movement, market context or actual UK access.
The themes to watch
| Theme | Why it matters | How to frame it for UK readers |
|---|---|---|
| Oral semaglutide | Oral semaglutide is the main route story behind Rybelsus and newer U.S. oral Wegovy interest. | Explain molecule and route carefully. Do not imply a UK weight-loss tablet launch unless a UK source confirms it. |
| Higher-dose semaglutide | Higher doses may affect comparisons with tirzepatide and other next-generation medicines. | Keep injection and tablet stories separate. A higher-dose injection result is not an oral tablet update. |
| CagriSema | The semaglutide-plus-amylin combination is one of Novo Nordisk’s key attempts to compete in next-generation obesity treatment. | Describe it as investigational where appropriate, and avoid treating it as a current UK option. |
| Amylin and combination therapies | The next phase of obesity medicine may not be GLP-1 alone. | Useful for future-facing explainer content, but not a current access answer. |
What not to overclaim
Do not turn an abstract, congress session or company presentation into a launch promise. Do not say a medicine is “coming to the UK” unless there is a clear UK regulatory or company access statement. Do not merge oral semaglutide, Rybelsus, Wegovy pill and every future tablet into one product. Those shortcuts may help a headline, but they make the reader less informed.
What GLP1 Tablets should publish from this
The strongest content is a rolling ECO 2026 update page that starts with the distinction between evidence and access. As data lands, it can be grouped into three buckets: oral/tablet relevance, injection/comparator relevance and future pipeline relevance. That lets the site move quickly without sacrificing the UK-first answer.
Helpful next reads: Trial news, Oral GLP-1 evidence library, and Are GLP-1 tablets available in the UK?.
Sources
- ECO 2026: congress dates and event information
- Novo Nordisk Science Hub: ECO 2026 programme
- Novo Nordisk Science Hub: semaglutide in clinical practice session
- Novo Nordisk Science Hub: amylin-based therapies session
Bottom line
ECO 2026 is a genuine watch-this-space moment for GLP-1 coverage. The best angle is not hype. It is careful, dated pipeline reporting that explains what the new data does and does not change for UK readers.